Employees: 1,133
Size Hvsen Biotechnology (300871.SZ) is a China Health Care company (Biotechnology) with a market value of $553M, the 3443rd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥18.78 on 18 Nov 2026.
Performance Over six months the shares fell 22.0%, against -13.8% for the median peer and -20.0% for the China market (cap-weighted) — 7th lowest of 19 in its peer set.
Growth Revenue grew 2.4% over the last twelve months (peer median +7.7%); the operating margin is 16.9% (peer median -49.9%).
Valuation It trades at 11.7× forward earnings against a peer median of 31.1× (cheapest of 7).
Capital Return on invested capital runs 1.8 points above its cost of capital (9.6% WACC).
Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.71B | CN¥1.68B | CN¥1.20B | CN¥1.02B | CN¥1.02B |
| Revenue growth | — | +40% | +18% | 0% | — |
| Gross profit | CN¥650M | CN¥484M | CN¥159M | CN¥164M | CN¥196M |
| EBITDA | n/a | CN¥398M | CN¥131M | CN¥127M | CN¥124M |
| Net income | CN¥324M | CN¥253M | -CN¥20.2M | CN¥16.8M | CN¥52.7M |
| Free cash flow | -CN¥159M | CN¥149M | -CN¥143M | -CN¥77.2M | -CN¥323M |
| Capital expenditure | CN¥420M | CN¥96.9M | CN¥194M | CN¥184M | CN¥429M |
| Total debt | CN¥678M | CN¥468M | CN¥1.20B | CN¥1.00B | CN¥984M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300871.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.1% | -15.3% | 5th highest of 21 |
| 6-month return | -22.0% | -13.8% | 7th lowest of 19 |
| Distance from 52-week high | -42.4% | -47.6% | 8th highest of 21 |
| Revenue growth (TTM) | +2.4% | +7.7% | 7th lowest of 17 |
| Operating margin | 16.9% | -49.9% | 2nd highest of 17 |
| Forward P/E | 11.7× | 31.1× | cheapest of 7 |
| ROIC minus cost of capital | +1.8 pp | -3.8 pp | 2nd highest of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Hvsen Biotechnology 300871.SZ | China | $553M | -22% | +2% | 17% | 11.7× | n/a | n/a |
| Sana Biotechnology SANA | United States | $554M | -41% | n/a | n/a | n/a | n/a | n/a |
| Wave Life Sciences WVE | United States | $546M | -55% | -35% | -321% | n/a | n/a | n/a |
| Climb Bio CLYM | United States | $546M | -12% | n/a | n/a | n/a | n/a | n/a |
| Boji Medical Technology 300404.SZ | China | $561M | -6% | +32% | 4% | 69.3× | 31.9% | +27.2% |
| Frontage 1521.HK | Hong Kong | $542M | +113% | +10% | 8% | 24.6× | 14.3% | +15.4% |
| Genfit GNFT.PA | France | $571M | +22% | +28% | -130% | 431.5× | 39.8% | +143.5% |
| Ascletis Pharma 1672.HK | Hong Kong | $571M | -72% | -59% | -71,976% | n/a | n/a | n/a |
| 4D Molecular Therapeutics FDMT | United States | $578M | +23% | +79,952% | -226% | n/a | n/a | n/a |
| Beijing Bohui Innovation Biotechnology 300318.SZ | China | $518M | -20% | -1% | -13% | n/a | n/a | n/a |
| Alebund Pharmaceuticals (Jiangsu) 9637.HK | Hong Kong | $595M | n/a | +674% | -495% | n/a | n/a | n/a |
| LongBio Pharma (Suzhou) 1779.HK | Hong Kong | $510M | n/a | n/a | n/a | n/a | n/a | n/a |
| Valneva VLA.PA | France | $508M | -6% | -27% | -87% | n/a | n/a | n/a |
| Anhui Huaheng Biotechnology 688639.SS | China | $605M | -45% | +7% | 3% | 22.3× | n/a | n/a |
| Surrozen SRZN | United States | $605M | +17% | +192% | -485% | n/a | n/a | n/a |
| Design Therapeutics DSGN | United States | $606M | -15% | n/a | n/a | n/a | n/a | n/a |
| Beijing Scitop Bio-Tech 300858.SZ | China | $501M | -28% | +4% | 8% | 21.5× | n/a | n/a |
| Sinotherapeutics 688247.SS | China | $494M | -19% | -17% | 0% | n/a | 29.4% | +7.0% |
| Liaoning Dingjide Petrochemical 603255.SS | China | $490M | -24% | +70% | 5% | 37.5× | n/a | n/a |
| Getein Biotech 603387.SS | China | $625M | -13% | +8% | 21% | n/a | -8.9% | -1.3% |
| CHO Pharma 6586.TWO | Taiwan | $488M | +24% | -47% | -17,694% | n/a | n/a | n/a |